We are live on ! Find out more
BJCM

Blue Jay Capital Management Portfolio holdings

AUM $147M
1-Year Est. Return 64.18%
This Fund
S&P 500
This Quarter Est. Return
+15.38%
1 Year Est. Return
+64.18%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$203M
AUM Growth
+$37.7M
Cap. Flow
+$16.9M
Cap. Flow %
8.33%
Top 10 Hldgs %
53.62%
Holding
27
New
12
Increased
1
Reduced
8
Closed
6

Top Buys

Rank Stock Value
1
BIIB icon
Biogen
BIIB
+$13.1M
2
GMED icon
Globus Medical
GMED
+$10.9M
3
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$9.34M
4
NVRO
NEVRO CORP.
NVRO
+$9.06M
5
NUVA
NuVasive, Inc.
NUVA
+$8.95M

Top Sells

Rank Stock Value
1
ALXN
Alexion Pharmaceuticals
ALXN
+$11M
2
HOLX
Hologic
HOLX
+$11M
3
LH icon
Labcorp
LH
+$10.9M
4
BSX icon
Boston Scientific
BSX
+$10.8M
5
SHPG
Shire pic
SHPG
+$10.6M

Sector Composition

Rank Sector Weight
1 Healthcare 78.31%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TSRO
1
DELISTED
TESARO, Inc.
TSRO
$13M 6.4%
84,649
-5,046
-6% -$822K
BIIB icon
2
Biogen
BIIB
$29.9B
$12.7M 6.23%
+46,320
New +$13.1M
GMED icon
3
Globus Medical
GMED
$10.4B
$11.8M 5.82%
+400,000
New +$10.9M
IRWD icon
4
Ironwood Pharmaceuticals
IRWD
$611M
$11.5M 5.66%
805,950
-116,259
-13% -$1.59M
QGENF
5
DELISTED
QIAGEN NV
QGENF
$11.3M 5.55%
390,000
-48,572
-11% -$1.41M
BMY icon
6
Bristol-Myers Squibb
BMY
$127B
$10.9M 5.35%
200,000
+30,000
+18% +$1.65M
CLVS
7
DELISTED
Clovis Oncology, Inc.
CLVS
$9.55M 4.7%
150,000
-148,982
-50% -$9.06M
WMGI
8
DELISTED
Wright Medical Group Inc
WMGI
$9.53M 4.68%
+306,165
New +$8.3M
ABMD
9
DELISTED
Abiomed Inc
ABMD
$9.39M 4.62%
+75,000
New +$8.69M
NVRO
10
DELISTED
NEVRO CORP.
NVRO
$9.37M 4.61%
+100,000
New +$9.06M
INCY icon
11
Incyte
INCY
$23.5B
$9.31M 4.58%
69,678
-39,693
-36% -$5.05M
BCR
12
DELISTED
CR Bard Inc.
BCR
$9.3M 4.57%
37,419
-14,958
-29% -$3.61M
BMRN icon
13
BioMarin Pharmaceuticals
BMRN
$11.5B
$9.22M 4.53%
+105,000
New +$9.34M
NUVA
14
DELISTED
NuVasive, Inc.
NUVA
$9.21M 4.53%
+123,317
New +$8.95M
PRAH
15
DELISTED
PRA Health Sciences, Inc.
PRAH
$9.13M 4.49%
+140,000
New +$8.25M
CELG
16
DELISTED
Celgene Corp
CELG
$9.07M 4.46%
+72,902
New +$8.72M
VRTX icon
17
Vertex Pharmaceuticals
VRTX
$121B
$8.77M 4.31%
+80,161
New +$7.06M
EW icon
18
Edwards Lifesciences
EW
$47.6B
$8.47M 4.16%
270,000
-39,087
-13% -$1.22M
MDRX
19
DELISTED
Veradigm Inc. Common Stock
MDRX
$7.48M 3.68%
+590,000
New +$7M
AKRX
20
DELISTED
Akorn Inc
AKRX
$7.22M 3.55%
+300,000
New +$6.53M
DERM
21
DELISTED
Dermira, Inc.
DERM
$7.16M 3.52%
210,000
-140,000
-40% -$4.52M
BSX icon
22
Boston Scientific
BSX
$65.8B
– –
-498,303
Closed -$10.8M
HOLX
23
DELISTED
Hologic
HOLX
– –
-273,478
Closed -$11M
LH icon
24
Labcorp
LH
$24.3B
– –
-98,940
Closed -$10.9M
RMD icon
25
ResMed
RMD
$28.3B
– –
-145,000
Closed -$9M
1
2

Similar funds

BCM
Breithorn Capital Management New York $141M AUM 41.82% 1-Year Est. Return
RJA
Robshaw & Julian Associates Williamsville, New York $140M AUM 13.69% 1-Year Est. Return
RP
Ridgegate Proprietary Sydney, Australia $154M AUM 25.47% 1-Year Est. Return
ACPVT
ABS Capital Partners V Trust Baltimore, Maryland $123M AUM
SFA
Staton Financial Advisors Charlotte, North Carolina $118M AUM 11.07% 1-Year Est. Return
KL
Kinsight LLC Birmingham, Alabama $176M AUM 17.21% 1-Year Est. Return
KFS
Kissinger Financial Services Hunt Valley, Maryland $100M AUM 6.22% 1-Year Est. Return
FHC
First Houston Capital Houston, Texas $100M AUM 23.45% 1-Year Est. Return

Blue Jay Capital Management's Q1 2017 Portfolio in Review

As of Q1 2017, Blue Jay Capital Management held 27 positions worth $203M, up 23% from $166M the previous quarter. Its ten largest holdings account for 54% of the portfolio.

Blue Jay Capital Management deployed $16.9M of net new capital in Q1 2017, opening 12 new positions and adding to 1 existing holding. Its largest new stake was Biogen: 46,320 shares worth $12.7M.

By sector, the portfolio is most concentrated in Healthcare at 78% of assets, down from 79% a quarter earlier.

On the sell side, the largest reduction was Clovis Oncology, Inc., an estimated $9.06M trimmed.

  • Blue Jay Capital Management's largest Q1 2017 buy was Biogen: 46,320 shares worth $12.7M.
  • Blue Jay Capital Management added most to Bristol-Myers Squibb in Q1 2017, an estimated $1.65M increase.
  • Blue Jay Capital Management's biggest Q1 2017 reduction was Clovis Oncology, Inc., cutting an estimated $9.06M.
  • Blue Jay Capital Management fully exited Alexion Pharmaceuticals in Q1 2017, selling an estimated $11M.
  • Blue Jay Capital Management's ten largest holdings make up 54% of its $203M portfolio in Q1 2017.
  • Blue Jay Capital Management opened 12 new positions and closed 6 in Q1 2017.
  • Blue Jay Capital Management's portfolio value rose 23% quarter-over-quarter to $203M.

Based on Blue Jay Capital Management's 13F filing for Q1 2017, filed 12 May 2017.